Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-HOBA to Prevent Early Recurrence of Atrial Fibrillation
NCT04433091Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 2-hydroxybenzylamine in Atrial fibrillation (AFib), sponsored by Vanderbilt University Medical Center. Started May 2020; status: completed.
02
Drugs
2-hydroxybenzylamine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04433091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04433091.